Medincell - UZEDY®: Q3 U.S. Net Sales Reach $85M, Up 96% Year-on-Year; 2026 Revenue Outlook Raised to $290-310M

UZEDY® U.S. net sales rose 96% year-on-year to $85 million in Q3 2026, according to results reported by Teva, Medincell’s partner. Teva raised its 2026 UZEDY® revenue outlook to $290–$310 million from $270–$290 million; nine-month 2026 U.S. sales were $225 million, above the $191 million recorded for full-year 2025.

Analysis

The higher outlook is a meaningful improvement in the product’s trajectory, but not automatically a material revision to Teva’s consolidated earnings: the key translation is incremental contribution after launch costs, rebates and any partner economics, none of which are provided. The new outlook midpoint is about 7% above the old midpoint; the Q3 sales pace annualizes above the new range, but one quarter is not a dependable run rate.

Near term, the likely catalyst is whether Teva’s next update confirms continued demand and converts sales growth into profitable contribution. For MedinCell, UZEDY could have greater equity sensitivity, but the commercial signal cannot be valued without its royalty or other economic terms and the resulting revenue contribution. Verify those terms and any company-level guidance before treating the sales beat as an earnings beat.

Over 6–18 months, sustained adoption could strengthen Teva’s differentiated-product mix and improve the case for MedinCell’s partnered-product model. The countercase is that strong growth from a smaller base may be priced in, while competing long-acting antipsychotic treatments constrain share and payer access or launch spending limits profit conversion. A slowdown in quarterly sales, unchanged MedinCell guidance despite the sales growth, or weak profitability conversion would falsify the bullish read.

Key Decisions for Investors

• TEVA: Treat as a positive but bounded fundamental signal, not a stand-alone buy catalyst. Reassess after the next update for product-level profitability or a consolidated guidance change; trim the thesis if sales growth decelerates or incremental contribution fails to show up.
• MEDCL: Put on an event-driven watchlist rather than extrapolating UZEDY sales directly into earnings. Verify royalty terms, reported UZEDY-related revenue and any guidance revision; consider exposure only if the disclosed economics confirm meaningful, recurring participation.
• Monitor long-acting antipsychotic competition and payer access over the next 1–3 months. If Teva’s subsequent reported sales fall materially below the Q3 pace or its outlook is not maintained, remove the growth-premium thesis; do not assume a single quarter’s annualized pace is sustainable.